A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
Public ClinicalTrials.gov record NCT01809327. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the effectiveness of the co-administration of canagliflozin and metformin extended release (XR) compared with canagliflozin alone, and metformin XR alone in patients with type 2 diabetes mellitus with inadequate control despite treatment with diet and exercise. The safety and tolerability of canagliflozin will also be assessed.
Study identification
- NCT ID
- NCT01809327
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,186 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 3, 2013
- Primary completion
- Dec 1, 2014
- Completion
- Dec 1, 2014
- Last update posted
- Jul 10, 2017
2013 – 2014
United States locations
- U.S. sites
- 52
- U.S. states
- 22
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Encinitas | California | — | — |
| Not listed | Newport Beach | California | — | — |
| Not listed | Northridge | California | — | — |
| Not listed | Norwalk | California | — | — |
| Not listed | Rancho Cucamonga | California | — | — |
| Not listed | Walnut Creek | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Northglenn | Colorado | — | — |
| Not listed | Hialeah | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Opa-locka | Florida | — | — |
| Not listed | Perry | Georgia | — | — |
| Not listed | Evansville | Indiana | — | — |
| Not listed | Mandeville | Louisiana | — | — |
| Not listed | Metairie | Louisiana | — | — |
| Not listed | Sunset | Louisiana | — | — |
| Not listed | Flint | Michigan | — | — |
| Not listed | Kalamazoo | Michigan | — | — |
| Not listed | Royal Oak | Michigan | — | — |
| Not listed | Troy | Michigan | — | — |
| Not listed | Olive Branch | Mississippi | — | — |
| Not listed | Picayune | Mississippi | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | West Seneca | New York | — | — |
| Not listed | Hickory | North Carolina | — | — |
| Not listed | Mooresville | North Carolina | — | — |
| Not listed | Franklin | Ohio | — | — |
| Not listed | Mason | Ohio | — | — |
| Not listed | Perrysburg | Ohio | — | — |
| Not listed | Zanesville | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Yukon | Oklahoma | — | — |
| Not listed | Tualatin | Oregon | — | — |
| Not listed | Fleetwood | Pennsylvania | — | — |
| Not listed | Norristown | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Rapid City | South Dakota | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Bellaire | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Pearland | Texas | — | — |
| Not listed | Plano | Texas | — | — |
| Not listed | Bountiful | Utah | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Danville | Virginia | — | — |
| Not listed | Norfolk | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.
Recently updated Diabetes Mellitus, Type 2 trials
Other public records listing Diabetes Mellitus, Type 2. Sorted by last update posted; newest first. Not a recommendation.
- NCT06920355: Community Pharmacy Produce Prescriptions Active, not recruiting
- NCT07784270: A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight Not yet recruiting
- NCT07783802: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Not yet recruiting
- NCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Recruiting
- NCT07590193: A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus Recruiting
- NCT07242469: A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01809327, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2017 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01809327 live on ClinicalTrials.gov.